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INTRODUCTION
Pleural effusion — pathological content in the pleural cav-
ity — is a comparatively frequent complication of various
diseases. No data of large-scale epidemiological trials are
available; however, the number of pleural pathology pa-
tients is estimated at 3000 cases per million population a
year (Hooper, 2010). Malignancy is one of the most fre-
quent causes of pleural fluids (Rodriguez-Pandero, 2003).
Upon examination of the pleural puncture fluid the presence
of malignant effusion is considered to be proven if malig-
nant cells are detected in cytological examination; however,
the mean sensitivity of cytological examination is approxi-
mately 60% and depends on sample preparation, the experi-
ence of the cytologist and on tumour type (Hooper, 2010).
The most informative method of diagnosing malignant
pleural effusion is diagnostic thoracoscopy, which enables
collection of pathologically altered tissue samples under
visual control and proving the diagnosis histological; how-
ever, in practice faster, cheaper, and less invasive proce-
dures are often required for the specification of the patient’s
diagnosis. Thus, new markers that are sufficiently sensitive
to prove the probability of malignancy are being sought.
Cancer antigen Ca-125 is a high molecular mass protein,
which is produced by epithelial ovary cancers and mesothe-
lial cells. Ca-125 is most frequently used to monitor the re-
sults of ovarian cancer therapy; however, Ca-125 can be
elevated in the event of both malignant and benign patholo-
gies, probably because of the involvement of serous mem-
branes and the irritation of mesothelial cells (Miralles,
2003; How et al., 2006). The mechanism of this process
is not fully known yet. Levels of Ca-125 are most fre-
quently estimated in blood serum, while the levels in serous
cavity fluids tend to be more informative (Korczynski,
2009).
CEA (carcinoembryonic antigen) is a glycoprotein involved
in cell adhesion, which is produced during the embryonic
development. The synthesis of CEA ceases upon birth;
however, elevated levels of CEA are observed detected
in patients with colorectal, pancreatic, lung and breast can-
cer, in smokers, cirrhosis patients, as well as in certain
other cases. Although CEA is not a specific indicator, the
level of CEA can increase 4–8 times before the clinical
symptoms caused by a tumour develop (Nicholson et al.,
2014).
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The significance of carbohydrate (cancer) antigen 125 (Ca-125) and carcinoembryonic antigen
(CEA) tumour markers levels in differential diagnostics of malignant and benign pleural effusion
was studied. Within this prospective study, 121 patients with fluids of various aetiology in the
pleural cavity were analysed. Malignant pleural effusion was detected in 55 patients, parapneu-
monic effusion in 28 patients, transudative effusion of cardiac origin in 31 patients, pancreatitis in
one patient and tuberculous pleurisy in five patients. The highest accuracy in diagnosis of malig-
nancy was observed for Ca-125 and CEA levels in the pleural fluid: 75.2% at cut-off value  1452
U/mL and 76.9% at cut-off value  6.58 ng/mL, respectively. We conclude that the level of tumour
markers in pleural fluid has additional diagnostic significance in the differential diagnosis of malig-
nant and benign pleural effusions.
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A hypothesis can be brought forward: tumour markers Ca-
125 and CEA in pleural effusion are diagnostic markers of
malignancy.
The goals of the research were:
1. To determine the Ca-125 and CEA levels in serum and
pleural effusion, as well as Ca-125 and CEA effusion/serum
ratios in patients with pleural effusion;
2. To compare the Ca-125 and CEA levels in patients with
malignant pleural effusion and those with pleural effusions
of different aetiology;
3. To establish diagnostic validity of tumour markers Ca-
125 and CEA in differential diagnosis of pleural effusion.
MATERIALS AND METHODS
The research protocol was confirmed by the Ethics Com-
mittee of Rîga Stradiòð University. An approved informed
consent form was signed from all subjects.
In the period from 1 August 2008 to 22 April 2013, 121 pa-
tients consecutively admitted at the 2nd Pulmonology De-
partment, Gaiïezers Clinic of Rîga East Clinical University
Hospital, with radiological and ultrasound findings of fluid
in the pleural cavity, were included in the study. All patients
included in the study were subject to pleural puncture in ac-
cordance with clinical indications. Light’s criteria (Light et
al., 1972) for the differentiation between exudative effusion
and transudative effusion were determined and clinical and
cytological analysis of pleural fluid sample was performed.
Patients in whom clinical analysis revealed the count of
monomorphonuclear cells to be > 95%, were subject to
blind pleural biopsy, which involves collection of core bi-
opsy samples through the chest wall for histological exami-
nation. Venous blood samples and pleural effusion samples
were collected from each patient in an EDTA vacutainer,
centrifuged for 10 minutes at 3000 rpm to obtain plasma
samples and stored at –80 oC until assayed. Ca-125 and
CEA were measured with ELISA using an Abbott Architect
device according to the manfacturer’s protocol. In order to
draw conclusions on the clinical significance of the mark-
ers, the sensitivity and specificity of both marker levels in
serum and punctate as well as the proportion of markers in
punctate/serum were calculated. Receiver operating charac-
teristic (ROC) curves and area under the curve (AUC)
analysis were estimated. Pleural fluid was considered to be
malignant if malignant cells were found in the pleural fluid,
or if the patient had had a previously confirmed malignant
disease and no other cause for the presence of pleural fluid
was found (Sahn, 1997). Diagnosis of tuberculous pleurisy
was confirmed by finding specific changes — tuberculous
granulomas during the histological examination of the pleu-
ral fluid. Parapneumonic pleurisy or pleural empyema was
diagnosed in patients with acute onset of the disease, febrile
temperature, chest pain, infiltrates in chest X-Ray examina-
tion or computed tomography scans and positive bacterial
culture in pleural cavity, in case other causes were ex-
cluded. Transudative effusion was diagnosed in cardiac
failure patients based on signs of cardiac failure (peripheral
oedema, history of known cardiac disease, echocardio-
gramm signs of cardiac failure or venous congestion in the
chest X-ray). Elevated lipase level in the pleural fluid was
used to diagnose pleurisy associated with pancreatitis.
Statistical analysis. Microsoft Excel and online software
for the Chi-squared 2 test with calculation of significant
differences (Preacher, 2001) were used for data processing,
as well as teh VassarStats online computer programme for
calculation of test sensitivity and specificity (Lowry,
1998–2012). In accordance with generally accepted princi-
ples in medical statistics, a p value of 0.05 was considered
to be the statistical significance threshold.
The arithmetic mean and standard deviation was used for
the description of quantitative variables; however, if the
data distribution did not conform to the norm, we used me-
dian and quartiles Q1 and Q3, as well as the range (mini-
mum and maximum values). The conformity of data to the
norm was checked using a Kolmogorov–Smirnov test and
histograms.
The Chi-squared 2 test was used for the comparison of cat-
egorical variables in different groups.
RESULTS
The presence of fluid in the pleural cavity was found in 121
patients from 30 to 90 years of age; 62 (57%) of the patients
were male. Malignant pleural effusion was detected in 55
patients, parapneumonic effusion in 28 patients, transuda-
tive effusion of cardiac origin in 31 patients, pancreatitis in
1 patient, and tuberculous pleurisy in 5 patients (Table 1).
In the group of malignant pleurisies, 11 patients had breast
cancer, 11 patients ovarian cancer, 19 patients lung cancer,
2 patients renal cancer, 2 patients cervical cancer, 2 gastric
cancer, 1 patient pancreatic cancer, 1 sarcoma, 1 pleural
mesothelioma, and unknown primary cancer in 5 patients
(Table 2). The sensitivity of cytological examination was
71%, specifity — 100%.
In order to determine whether statistically significant differ-
ences between Ca-125 and CEA in the pleural fluid of dif-
ferent aetiology exist, the groups of parapneumonic pleu-
T a b l e 1
BASELINE CHARACTERISTICS OF PATIENTS WITH PLEURAL EF-
FUSION, n = 121
Indicator n (%) or mean ± SD (range)
Age Years 70 (range 22–90)
Gender Male 62 (51%)
Female 59 (49%)
Diagnosis Cardiac transudate 31 (25.6%)
Parapneumonic effusions 28 (23.1%)
Malignant effusion 55 (45.5%)
Tuberculous effusion 5 (4.1 %)
Pancreatitis 1 (0.8%)
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risy, malignant pleural effusion and transudative effusion
were subject to further analysis. Median serum and pleural
fluid levels of Ca-125 and CEA were determined in all three
groups (Table 3). Tuberculous pleurisy and pleurisy due to
pancreatitis were not included in further analysis due to the
small number of patients.
In almost all cases (except Ca-125 effusion/serum ratio) the
highest accuracy was found when the cut-off or differentia-
tion of malignant effusion was set based on the 3rd quartile
rather than 1st or 2nd (Table 4). The accuracy ranged from
64% to 77% for CEA marker and from 58% to 75% for
Ca-125. Similarly, the sensitivity was also highest for
cut-offs based on the 75th percentile, while the specificity
was best at the 25th percentile. Thus, the highest accuracy
was found for Ca-125 effusion of 1452 U/ml (75.2%) and
for CEA effusion of 6.58 mg/ml (76.9%). Area under
curves was also highest in CA-125 in pleural effusion and
CEA in pleural effusion, 0.793 and 0.761, respectively (Ta-
ble 5, Figure 1).
DISCUSSION
In order to establish the probable significance of the Ca-125
tumour marker in differential diagnosis of pleurisy, 121 pa-
tients with fluid in the pleural cavity were examined.
It was found that higher accuracy and sensitivity either for
Ca-125 or CEA levels were found when the 75th percentile
was used as the cut-off value, while the highest specificity
was found using the 25th percentile as the cut-off value. The
highest positive predictive value was established for Ca-125
and CEA concentration in the pleural fluid, in contrast to
the concentration of these markers in the serum or ratios of
fluid/serum concentration. Thus, concentrations in pleural
fluid allow to make conclusions on its local production in
both impaired mesothelial cells (Ca-125) and malignant
cells. A high pleural puncture fluid/serum ratio of Ca-125
for malignant effusion in comparison with the fluid of other
origin in the pleural cavity can indicate limited systemic dif-
fusion.
Ma et al. (2013) retrospectively determined the level of
Ca-125 in blood serum in 2115 patients with chronic car-
diac failure aged over 85 and found that the Ca-125 level in
blood serum was significantly elevated in patients with fluid
in the pleural cavity and peripheral oedema. Durak-
Nalbantic et al. (2013) measured Ca-125 in the serum of 76
patients with cardiac failure and came to the same conclu-
sion: serum Ca-125 level was higher in patients with fluid
in the pleural and pericardial cavities. Turk et al. (2003),
compared cardiac failure patients with and without transu-
date in pleural cavity and healthy volunteers, and also found
that the Ca-125 level was significantly higher in patients
with cardiac failure and transudative effusion in pleural cav-
ity. In our study we did not find a signicant difference in
Ca-125 level in patients with cardiac failure and transuda-
tive effusion in the pleural cavity and in patients with ma-
lignant pleural effusion (p < 0.139); however, the difference
T a b l e 2
LOCALISATION OF PRIMARY CANCER IN PATIENTS WITH MA-
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T a b l e 3
MEDIAN SERUM AND PLEURAL FLUID LEVELS OF CA-125 AND CEA IN PATIENTS WITH TRANSUDATIVE EFFUSION, MALIGNANT EF-
FUSION AND PARAPNEUMONIC PLEURISY
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p1, significance between transudative effusion vs. malignant effusion
p2, significance between parapneumonic effusion vs. malignant effusion
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in levels in the pleural fluid did significantly differ (p <
0.001).
Choi et al. (2013) determined Ca-125 levels in pleural
puncture fluid of 326 patients and afterwards retrospectively
analysed its level in patients with various aetiology of the
pleural fluid. It was concluded that significant elevation of
Ca-125 occurred in patients with pleural fluid of malignant
origin (more than 1/3 of the patients had Ca-125 levels of
>600 U/ml), but the difference was statistically insignificant
in patients with transudative effusion and fluid of benign ae-
tiology in the pleural cavity. No significant differences in
Ca-125 levels were detected for patients with cancer of dif-
ferent localisation as well, which leads to the conclusion
that the impairment of mesothelial cells does not depend on
the type of cancer. According to our calculations, the medial
level of Ca-125 in malignant pleural effusion was 1452
U/ml and the difference in its level in the event of malignant
effusions from either transudative effusion or parapneu-
T a b l e 4
CA-125 (U/ML) AND CEA (NG/ML) AS DIAGNOSTIC INDICATORS






CEA Effusion 0.76 81.8% 36.4% 57.0%
1.99 74.5% 65.2% 69.4%
6.58 58.2% 92.4% 76.9%
Serum 1.40 70.9% 31.8% 49.6%
2.77 60.0% 56.1% 57.9%
4.68 41.8% 87.9% 66.9%
Effusion/
serum
0.40 90.9% 28.8% 57.0%
0.71 72.7% 56.1% 63.6%
1.58 49.1% 84.8% 68.6%
Ca-125 Effusion 347 85.5% 51.5% 66.9%
768 70.9% 72.7% 71.9%
1452 54.5% 92.4% 75.2%
Serum 56 83.6% 30.3% 54.5%
167 67.3% 63.6% 65.3%
344 41.8% 86.4% 66.1%
Effusion/
serum
2.59 80.0% 34.8% 55.4%
4.62 60.0% 57.6% 58.7%
9.56 29.1% 81.8% 57.9%
T a b l e 5
AREA UNDER THE CURVE FOR CEA LEVEL IN EFFUSION, SE-
RUM, AND EFFUSION/SERUM RATIO AND FOR CA-125 LEVEL IN














CEA Effusion 0.761 0.047 0.001 0.668 0.854
Serum 0.609 0.054 0.004 0.503 0.714
Effusion/
serum
0.741 0.046 0.001 0.651 0.832
Ca-125 Effusion 0.793 0.042 0.001 0.710 0.876
Serum 0.705 0.048 0.001 0.611 0.799
Effusion/
serum
0.625 0.051 0.018 0.524 0.726
Fig. 1. Receiver operating characteristic
(ROC) curves for CEA level in effusion, se-
rum, effusion/serum ratio and for Ca-125
level in effusion, serum, effusion/serum ra-
tio.
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monic pleurisy cases was statistically significant (p <
0.001).
Kalantri et al. (2007) analysed non-specific elevation of
Ca-125 in 38 patients with pleural fluid and 46 patients with
ascites (including either exudative effusion or transudative
effusion). It was found that the elevation of Ca-125 was sta-
tistically significant in patients with ascites of any aetiol-
ogy, which allowed to conclude that mesothelial cells of the
abdominal cavity have a higher capacity for producing this
substance.
Bielsa et al. (2009) determined various tumour markers, in-
cluding CEA and Ca-125, in 224 patients with confirmed
malignant pleural effusion in the pleural fluid. They found
that a level of Ca-125 above 1000 U/ml in combination with
fragments of cytokeratin 19 – CYFRA 21-1 of >100 ng/ml
was significantly associated with lower survival (Bielsa et
al., 2009).
Xu et al. (2015) determined the level of CEA in 60 malig-
nant and 58 benign pleural fluids and established that in 54
patients with malignant pleural effusion the level of CEA
was >5.5 ng/ml and at this cut-off value the combination of
CEA with tumour marker Type II membran protein RCAS
yielded sensitivity of 98.3 and specificity of 91.4% (Xu et
al., 2015); according to our data, at a cut-off value of 6.58
ng/ml the sensitivity of CEA was 58.2% and specificity
92.4%.
Son et al. (2015) analysed 47 benign and 52 malignant
pleural effusions and compared the diagnostic values of tu-
mour markers CD66c, CEA, Ca 19-9, and CYFRA 21-1 in
pleural puncture fluid. They found that CEA has the highest
diagnostic value with sensitivity of 87.2% and specificity of
92.3% (Son et al., 2015). The sensitivity was considerably
lower in our data, while specificity was similar — 92.4%.
CONCLUSIONS
The analysis of our data and that of several authors indicate
that:
1. In cases of malignant effusion the level of Ca-125 and
CEA are significantly higher in pleural fluid.
2. The relatively high accuracy of Ca-125 and CEA, upon
determining them in pleural fluid, allows use of these mark-
ers as additional diagnostic criteria for the determination of
malignancy; however, neither the Ca-125 and CEA level in
serum, nor puncture fluid/serum ratio have considerable di-
agnostic significance.
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AUDZÇJA MARÍIERU Ca-125 UN CEA DIAGNOSTISKÂ VÇRTÎBA MALIGNU PLEIRAS ÐÍIDRUMU DIFERENCIÂL-
DIAGNOSTIKÂ
Audzçja maríieru karbohidrâta antigçna 125 (Ca-125) un karcinoembrionâlâ antigçna (CEA) lîmeòu nozîme ïaundabîgas un labdabîgas
etioloìijas pleiras ðíidruma diferenciâldiagnostikâ joprojâm tiek pçtîta. Ðai prospektîvajâ pçtîjumâ tika analizçts 121 pacients ar daþâdas
etioloìijas ðíidrumu pleiras dobumâ. Maligni pleiras eksudâti tika konstatçti 55 pacientiem, parapneimoniski pleirîti — 28 pacientiem,
kardiâlas etioloìijas transudâti —31 pacientam, pankreatogçns eksudâts — 1 pacientam, tuberkulozi pleirîti — 5 pacientiem. Visiem
pacientiem tika noteikti Ca-125 un CEA lîmeòi pleiras punktâtâ, serumâ un aprçíinâta to pleiras punktâta/seruma attiecîba. Visaugstâkâ
precizitâte ïaundabîgu pleiras eksudâtu diagnostikâ tika konstatçta Ca-125 un CEA lîmeòiem pleiras punktâtâ — attiecîgi 75,2% pie
robeþlîmeòa 1452 U/mL un 76,9% pie robeþlîmeòa 6.58 ng/mL. Mçs secinâjâm, ka audzçju maríieru Ca-125 un CEA lîmeòa noteikðanai
pleiras punktâtâ ir papildus diagnostiska nozîme ïaundabîgas un labdabîgas etioloìijas pleiras ðíidrumu diferenciâldiagnostikâ.
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